DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reclast (Zoledronic Acid) - Summary



Reclast contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption.

Reclast (zoledronic acid) is indicated for the following:

Postmenopausal Osteoporosis

††††† Reclast†is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Reclast†reduces the incidence of fractures (hip,†vertebral and non-vertebral osteoporosis-related fractures)†[ see Clinical Studies (14 .1)].

Paget's Disease of Bone

Reclast is indicated for treatment of Paget's disease of bone in men and women.†Treatment is indicated in patients with Pagetís disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease†[ see Clinical Studies (14 . 2 ) ].

See all Reclast indications & dosage >>


Published Studies Related to Reclast (Zoledronic Acid)

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. [2014]
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in

Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. [2013]
1 infusion of zoledronic acid... CONCLUSIONS: In this post hoc analysis based on postrandomization subgroups,

Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer. [2013]
lung cancer (NSCLC) with asymptomatic bone metastases (BMs)... CONCLUSIONS: Treatment with ZA and/or Sr-89 significantly extended the time to

Fracture risk and zoledronic acid therapy in men with osteoporosis. [2012]
osteoporosis... CONCLUSIONS: Zoledronic acid treatment was associated with a significantly

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. [2012]
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with

more studies >>

Clinical Trials Related to Reclast (Zoledronic Acid)

Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer [Recruiting]
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year [Recruiting]
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic acid during the previous 10-15 months.

Re-treatment of Patients With Paget's Disease Using Zoledronic Acid [Recruiting]
The purpose of this study is to demonstrate that patients with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5mg infusion of zoledronic acid.

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer [Recruiting]
The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has been established that zoledronate therapy may play a role in delaying and reducing the incidence of skeletal events. Researchers propose to evaluate the change in the uptake value of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU PET scans can successfully demonstrate and detect bony metastatic sites in prostate cancer.

In addition, investigators would like to evaluate the change in the level of the prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.

Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients [Recruiting]
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.

more trials >>

Reports of Suspected Reclast (Zoledronic Acid) Side Effects

Death (377)Pain (226)Arthralgia (210)Femur Fracture (154)Fall (153)Headache (137)Pain in Extremity (133)Nausea (121)Pyrexia (114)Myalgia (113)more >>

Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015